Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)

Why It Matters

The rating and target adjustment signal that analysts view Genmab as a steady, royalty‑rich biotech with limited upside, influencing institutional allocation in a sector where growth expectations are closely tied to pipeline milestones.

Key Takeaways

• Morgan Stanley keeps Equal Weight rating, cuts price target to $33.
• Q1 revenue jumps 25% to $896M, led by royalty growth.
• Operating profit steadies near $180M despite 25% expense rise.
• Royalty income climbs to $742M, driven by DARZALEX and Kesimpta.
• Genmab retains 2026 guidance, reflecting confidence in late‑stage pipeline.

Pulse Analysis

Genmab’s business model hinges on royalty streams from blockbuster antibodies it co‑develops with larger partners. In Q1 2026, royalty income surged to $742 million, accounting for most of the $896 million revenue total, underscoring the value of its collaborations on DARZALEX (for multiple myeloma) and Kesimpta (multiple sclerosis). This royalty‑centric revenue provides a relatively predictable cash flow compared with traditional biotech sales, allowing Genmab to fund R&D while delivering consistent earnings.

Morgan Stanley’s decision to maintain an Equal Weight stance while trimming the price target reflects a nuanced view of Genmab’s risk‑reward profile. The modest downgrade suggests the firm sees limited upside beyond the current valuation, given the company’s steady profit margins but rising operating costs. In a market where biotech valuations often swing on binary trial outcomes, analysts may be pricing in the uncertainty surrounding Genmab’s late‑stage pipeline, despite the solid top‑line growth.

Looking ahead, Genmab’s pipeline includes several late‑stage candidates poised for launch, which could diversify revenue beyond royalty dependence. However, the company must balance escalating R&D spend against the need to sustain profit margins. Investors should monitor trial readouts, partnership agreements, and the timing of new product rollouts, as these factors will dictate whether Genmab can translate pipeline progress into incremental earnings and potentially justify a higher valuation.